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ABSTRACT 
 
Hypertrophic cardiomyopathy is an inherited heart disease characterized 
by unexplained thickening of the left ventricle. Given its autosomal dominant 
method of inheritance, all first-degree family members of an HCM patient have a 
50% risk of inheriting the disease. Since family members are at high risk for 
disease, we consider HCM a disease of not just a single patient, but of a whole 
family. Medical guidelines propose that all first-degree family members seek 
HCM-related follow-up. In most cases the follow-up involves longitudinal clinical 
screening. In some cases genetic testing is also indicated for relatives.  
In an observational study of 361 HCM patients and family members, who 
were seen at a specialized HCM clinic in the Cardiovascular Genomics Center at 
Brigham and Women’s Hospital in Boston, MA, we show that only 39% of 
relatives pursued any HCM-related follow-up. In general, children of HCM 
patients were more likely to seek follow-up than siblings or parents of HCM 
patients. In cases where genetic testing was indicated for family members, 
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relatives were more likely to seek clinical than genetic screening. Yet, a large 
proportion did seek both types of testing.  
Genetic testing results seemed to influence the return by relatives for 
clinical follow-up. When a disease-causing genetic variant was identified in one 
individual, family members were more likely to have HCM-related follow-up than 
when no genetic variant was identified or no genetic testing was performed.   
This study provides initial insights into the causes for the low overall rate 
of familial follow-up for an inherited disorder. We recognize that relatives are lost 
to follow-up at the stage when the initial patient must transmit information about 
follow-up to his relatives. Of greater concern, our data suggests that patients may 
be misinterpreting negative genetic test results, which may reflect a mutation in a 
gene that has yet to be discovered, despite appropriate genetic counseling.  
 Determining what factors influence familial follow-up allows us to reassess 
current processes, so as to ensure that more at-risk family members receive 
evaluations. Providing clinical care to the entire HCM population is important for 
treatment of symptoms and prevention of sudden cardiac death, the most 
devastating outcome caused by HCM. With the use of genetic testing we are also 
able to identify HCM patients before any symptoms arise. Studying this 
asymptomatic population allows us to learn more about disease biology and 
progression with the end goal of finding a medical therapy to reverse or prevent 
HCM.  
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INTRODUCTION 
Hypertrophic Cardiomyopathy 
Hypertrophic Cardiomyopathy is a disease of the heart muscle 
characterized by left ventricular wall thickening or hypertrophy (LVH) that cannot 
be explained by an existing cause, such as pressure overload or metabolic 
abnormalities (Gersh, et al., 2011). At the cellular level, myocyte disarray and 
increased amounts of cardiac fibrosis occur with hypertrophy (Gersh, et al., 
2011). HCM affects about 1 in 500 people in the general population, and it is the 
most common cause of sudden cardiac death in young people (Maron, 1995).   
Clinical manifestations of HCM vary widely, with a broad range of disease 
severity and age of onset. Common symptoms include shortness of breath, 
especially upon exertion, chest pain, palpitations, orthostasis, presyncope, and 
syncope (Cirino & Ho, 1993). HCM patients can have any variety of these 
symptoms ranging from asymptomatic to progressive heart failure (Cirino & Ho, 
1993). Importantly, there is not always a correlation between the severity of 
symptoms that are experienced by a patient and the patient’s risk for life-
threatening ventricular arrhythmias or sudden cardiac death (SCD). Risk for 
arrhythmias or SCD may be high even in patients with very mild cardiac 
symptoms. There are even rare cases when the first presentation of disease is 
sudden cardiac death (Maron, 2000). For these reasons there is a great need for 
a method of screening that can detect the disease in the absence of symptoms. 
Normally left ventricular hypertrophy, the hallmark of HCM, presents at 
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adolescence or young adulthood, which is potentially related to pubertal 
development changes (Cirino & Ho, 1993). There are cases, however, of LVH 
presenting as early as infancy or childhood and also much later in life (Cirino & 
Ho, 1993).  
HCMNormal  
Figure 1. Gross and Histological Anatomy of HCM.  Figure 1 shows a 
comparison between a normal heart and an HCM heart. On a gross level, the left 
ventricle of an HCM heart has visible hypertrophy. Note the resultant changes in 
chamber size. Microscopically, myocytes in a normal heart have regular order, 
and there is minimal fibrosis. In an HCM heart there is myocyte disarray. The 
regular order of the cells is lost. The light pink areas are diffuse fibrosis. (Arad, 
Seidman, & Seidman, 2002) 
 
Genetic Basis for HCM 
Hypertrophic cardiomyopathy was first recognized as a familial disease 
inherited in an autosomal dominant pattern over 50 years ago (Hollman, 1960). 
Through linkage studies twenty years ago we discovered that HCM is caused by 
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mutations in genes coding for cardiac sarcomeric proteins (Ho, 2012). For this 
reason HCM is often referred to as the “disease of the sarcomere” (Thierfelder, et 
al., 1994). Over 1,000 HCM causing mutations have been discovered in at least 
8 genes either within or associated with the sarcomere, including beta-myosin 
heavy chain, cardiac myosin-binding protein C, cardiac troponin T, cardiac 
troponin I, essential myosin light chain, regulatory myosin light chain, alpha-
tropomyosin, cardiac actin, and titin  (Gersh, et al., 2011). The majority of 
mutations, about 80%, are in genes coding for myosin heavy chain and myosin 
binding protein C (Richard, et al., 2003). 
 
 
Figure 2. Model of Sarcomeric Proteins. Figure 2 shows the protein 
components of the sarcomere. These proteins are coded for by the genes that 
when mutated cause HCM. Myosin heavy chain and myosin binding protein C 
are the genes that are most commonly mutated in HCM patients. (Arad, 
Seidman, & Seidman, 2002) 
 
The number of mutations causing disease is constantly growing. Currently 
genetic testing can identify a mutation in approximately 40-50% of HCM patients. 
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Patients who have a family history of HCM have a higher mutation detection rate 
of up to 70%. Patients with no family history of disease, where the mutation may 
have arisen de novo, have a lower rate of detection at approximately 30-40% 
(Ho, 2012). Most of the discovered mutations are unique to a family. There are 
few instances of a single mutation explaining disease in unrelated patients (Ho, 
2012).  
Diagnosis of HCM 
 Clinical diagnosis of HCM occurs when unexplained LVH is identified, 
most often by a two-dimensional echocardiograph or more recently by magnetic 
resonance imaging (Maron, Seidman, & Seidman, 2004). Patients are most 
commonly diagnosed with HCM when they present with cardiac symptoms, have 
a murmur upon physical exam, have an abnormal electrocardiogram (ECG), or 
come to the doctor for family screening (Maron, Seidman, & Seidman, 2004). 
Sometimes a diagnosis may only occur after a patient has experienced an 
adverse event.  
The diagnosis of HCM can be difficult, as other conditions that cause LVH, 
including hypertensive heart disease, disorders of cardiac valves, athlete’s heart, 
or storage disease must be ruled out. The clinical management of these 
conditions is considerably different than that for HCM. Genetic testing can 
resolve an ambiguous diagnosis, because the identification of a disease-causing 
sarcomere mutation definitively differentiates HCM from other conditions where 
hypertrophy is present. 
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Management of HCM  
There is currently no treatment that can prevent or reverse HCM. There is, 
however, a three-pronged strategy to manage disease that includes treatment of 
symptoms, assessment of SCD risk, and counseling and screening. The 
counseling and screening aspect of management includes lifestyle 
recommendations, family screening, and genetic counseling (Ho, 2012a).  
The two most common symptoms of HCM are dyspnea upon exertion and 
chest pain. These symptoms are likely caused by diastolic dysfunction, or 
incomplete cardiac relaxation (Olivotto, et al., 2006). Beta-blockers or L-type 
calcium channel blockers are used to treat these symptoms as these medications 
prolong diastolic fill time (Ho, 2012a).  
Palpitations are common in HCM, a symptom that can indicate an 
underlying cardiac arrhythmia.  Atrial fibrillation, the most common HCM 
arrhythmia, prevents complete emptying of the cardiac atria, which can result in 
stagnant blood that can clot and lead to thromboembolism. Anticoagulants are 
prescribed to these patients with atrial fibrillation to address this risk (Ho, 2012).  
In about two thirds of HCM patients, disease is complicated by obstruction 
due to either hypertrophy that impinges into the outflow tract of blood or due to 
another HCM hemodynamic abnormality. The obstruction may either be at rest or 
only under provocation by exercise or tachycardic arrhythmias  (Maron, et al., 
2006). Vasodilators, typically used to treat symptoms in other cardiovascular 
diseases, can exacerbate the obstructive physiology and are contra-indicated in 
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HCM patients with obstructive disease (Ho, 2012). If patients become limited by 
symptoms relating to obstruction they can be treated with disopyramide. Patients 
with severely symptomatic obstructive HCM may consider having invasive septal 
reduction (Gersh, et al., 2011). Options for reduction include surgical myectomy 
and alcohol septal ablation, procedures that respectively excise or produce an 
infarct in the hypertrophied obstructive segment. Although these procedures 
improve blood flow through the heart and, in turn, cardiac symptomology they are 
not proven to increase lifespan or decrease SCD risk (Ho, 2012). 
In addition to managing symptoms we assess for sudden cardiac death 
risk. SCD risk is clinically assessed on the following five factors: personal history 
of resuscitated cardiac arrest, family history of SCD, becoming hypotensive upon 
exercising, discovery of ventricular ectopy, and a history of unexplained syncope 
(Cirino & Ho, 1993).  
Any patient with a personal history of sudden cardiac arrest will be 
advised to have an implantable cardioverter-defibrillator placed. Patients who 
have two or more of these risk factors have an increased risk for SCD, and may 
be advised to have an ICD placed to prevent SCD (Elliott, et al., 2000). There 
are, however, additional complications associated with ICDs, so the decision to 
implant a device should be assessed on a case-by-case basis (Czosek, et al., 
2012). 
There are a number of clinical measures used to identify and characterize 
additional risk factors for SCD. Physicians compile complete family histories of 
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SCD in affected family members. Exercise testing is used to monitor blood 
pressure response in a controlled clinical environment. Holter monitoring is used 
to detect ventricular ectopy over a longer time period than that which occurs in 
the clinical setting. These risk factors tests are repeated every 12 to 24 months, 
depending on the findings and symptoms, to identify the patient’s SCD risk 
throughout life and as disease progresses. 
Physicians devote considerable time to counseling HCM patients. Patients 
with HCM, dependent on the extent of disease, may be advised to avoid certain 
activities or situations, including competitive or endurance training, burst exertion, 
dehydration, and hypovolemia. These scenarios can be particularly dangerous to 
patients with obstructive HCM (Cirino & Ho, 1993). Although SCD has been 
documented in competitive athletes with HCM, (Maron, 2003) moderate aerobic 
exercise (that allows conversation) is recommended for HCM patients with 
minimal symptomology (Gersh, et al., 2011).  
The other arm of counseling involves family screening, because 
sarcomeric HCM is an inherited disease. In genetic disease, like HCM, 
physicians have the unique opportunity to treat not only the patient, but also the 
patient’s entire family. By identifying disease in family members early we can 
prevent future complications and assess for SCD risk (Ho, 2012). The clinical 
and genetic aspects and recommendations of screening family members will be 
discussed in the sections to follow. 
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Clinical Screening for Family Members 
 Since HCM is a familial disease that follows an autosomal dominant 
inheritance pattern, it is recommended that first-degree family members of an 
HCM patient undergo clinical screening. Proper clinical screening includes a 
physical, family history, two-dimensional echocardiogram and 12-lead ECG 
(Maron, Seidman, & Seidman, 2004). Clinical screening is focused on family 
members aged 12 to 18, because this is the most common time for disease to 
develop (Maron, Seidman, & Seidman, 2004). Patients in this age group should 
be seen every 12-18 months (Maron, Seidman, & Seidman, 2004). Historically, 
after reaching age 21 with a negative evaluation for HCM patients were thought 
not to carry the gene for disease, and they were deemed unaffected (Maron, 
Seidman, & Seidman, 2004). However recent information indicates the potential 
for late onset disease, and a negative evaluation at 21 years of age cannot rule 
out the future development of HCM. As such, continued clinical screening for 
patients older than 21 is recommended approximately every five years (Maron, 
Seidman, & Seidman, 2004). It is generally reasonable to defer screening in 
family members younger than 12 years old, because LVH is infrequent in this 
age group (Maron, Seidman, & Seidman, 2004).  
Genetic Testing 
 Ten years ago genetic testing for HCM moved from research laboratories 
to clinically available tests (Ho, 2012). There are two types of genetic tests, 
diagnostic and predictive. Diagnostic testing uses a candidate-gene approach 
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where a panel of sarcomere genes is sequenced. In addition to the sarcomere 
genes, a few genes associated with diseases that have similar clinical 
presentations, but can be explained by metabolic, storage, or mitochondrial 
disorders, are included (Arad, et al., 2005). This comprehensive test tries to 
identify the mutation that causes disease in an HCM patient.  
If a diagnostic test identifies a disease causing mutation there is an 
opportunity for predictive testing in the patient’s family members. Predictive 
testing is the targeted sequencing of the region of the gene where the previously 
identified mutation is located. Predictive testing only has the power to confirm or 
deny the presence of a known mutation. A predictive test cannot find any 
additional mutations (Ho, 2012). 
Interpreting Genetic Test Results 
 Proper interpretation of genetic test results is key to using genetic 
information clinically. Genetic test results yield probabilities instead of 
quantitative outcomes like other clinical tests (Ho, 2012). Once a DNA variant 
has been found in a gene coding for a sarcomeric protein, the laboratory 
attempts to determine the probability that the variant is pathogenic or disease 
causing (Ho, 2012). The probability a variant is pathogenic increases when family 
studies are performed. We look for segregation of the variant with clinical 
affection status in a large number of relatives. Other considerations that increase 
the likelihood that a variant is pathogenic include the absence of the variant from 
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large numbers of healthy normal individuals, and evidence that the variant alters 
a gene region that is highly conserved over evolutionary time.  
Classification of Variants 
 Several criteria are used to support the classification of a variant as 
pathogenic. These criteria were developed by the Laboratory for Molecular 
Medicine (LMM), which is the preferred genetic testing facility of the CVGC clinic. 
First, when there is significant data showing the variant segregating with disease 
in one or multiple families. Second, we call a variant pathogenic when there is 
moderate segregation data, and the variant is absent from a large number of 
controls, and the region of the genome where the variant occurs is evolutionarily 
conserved. Third, a variant can be called pathogenic in the absence of 
segregation data if it does not occur in a large, race-matched group of controls 
and we have convincing functional data about the variant, such as evidence that 
the variant causes HCM in an experimental model.  A DNA variant is designated 
as pathogenic if it causes a loss of function in a protein that is known to have a 
critical role in disease. Finally, if a variant arises de novo in a gene implicated in 
the disease, and genetic analyses confirm biologic parentage, it will be classified 
as pathogenic. In each of these cases we have confidence that the variant 
explains why the patient developed disease (Laboratory of Molecular Medicine, 
2011). 
 When we still believe the variant is disease causing, but we have less 
definitive information about the variant, the variant is called likely pathogenic. The 
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first case is when we have no segregation information, but the variant is absent 
from a large, race-matched group of controls, evolutionarily conserved, and 
predicted as pathogenic by the LMM’s computational assessment (Jordan, et al., 
2011). A second case occurs when we have moderate segregation data, 
evolutionary conservation, but no information about the variant’s frequency in a 
control population or the encoded protein’s function. Third, the variant has some 
segregation data, evolutionary conservation, and rare frequency in a control 
population. The last situation termed likely pathogenic is when we find a novel 
variant that causes loss of function in the protein it encodes, but we have yet to 
determine the role the protein plays in disease. As we gain a better 
understanding of disease mechanisms and variant frequencies these variants 
can be upgraded or downgraded in significance (Laboratory of Molecular 
Medicine, 2011). 
The most ambiguous variant classification is unknown significance. When 
we find a variant of unknown significance (VUS) we do not have sufficient data to 
determine if it is disease causing or if it is a benign polymorphism. A variant that 
is absent in a large group of controls but has no other information available is a 
variant of unknown significance. A novel variant that has been predicted to cause 
disease by computational assessment only is a VUS. Also, any variant that has 
conflicting information about whether or not it is disease causing will be called a 
VUS. Detecting variants of unknown significance does not give us any additional 
information for clinical use (Laboratory of Molecular Medicine, 2011).  
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Possible Clinical Outcomes from Genetic Test Results 
 There are a number of possible outcomes for genetic test results that 
impact how clinical follow-up for family members should proceed. In the absence 
of any genetic test results all first-degree relatives should be longitudinally 
clinically followed by a cardiologist as outlined in the section on clinical 
screening. The following will explain in which cases genetic testing can narrow 
the focus of clinical screening to just those family members who are at-risk to 
develop inherited disease.  
When diagnostic testing can identify a variant that is classified as 
pathogenic or likely pathogenic, all first-degree family members can pursue 
predictive genetic testing with a level of confidence that their risk for disease will 
be ascertained. Those who are negative for the mutation are not at-risk to 
develop HCM. Those who are positive for the mutation are at-risk, need to be 
longitudinally screened by a cardiologist, and should have all of their first-degree 
relatives tested as well. This initiates a process termed cascade screening. 
When diagnostic testing identifies a variant of unknown significance, there 
is ambiguity as to whether or not the variant causes disease. Defining whether or 
not additional clinically affected family members carry the variant of unknown 
significance can be helpful. If the variant segregates with disease in the family 
the classification can be updated to pathogenic or likely pathogenic. If it does not 
segregate with disease in the family, the variant can be re-classified as likely 
benign. This is useful not only for the family, but also for our general knowledge 
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of disease-causing mutations and their classifications.  As long as uncertainty 
exists, all family members need longitudinal clinical screening.  
Last, if a diagnostic test fails to identify a variant we call this a negative 
genetic test result. The proband’s HCM may still be familial in nature, but there is 
no clear genetic marker to help focus further clinical screening of family 
members. All first-degree relatives should continue their longitudinal screening. 
Importantly, a negative genetic test result means only that we failed to identify a 
disease-causing variant in the small panel of HCM genes we sequenced. 
Currently we do not know all of the genes involved in causing or modifying HCM. 
Until we have discovered all of them a negative genetic test result can still imply 
familial disease. In time, with the discovery of more genes that modify and cause 
HCM and the development of more comprehensive sequencing techniques, we 
may be able to re-test this group of patients to find novel disease-causing 
mutations.  
Clinical Genetics 
 Clinically genetic testing in HCM patients has limited utility in impacting 
patient management. While the identification of a mutation clarifies the patient’s 
diagnosis of HCM, genetic test results are not likely to directly change the 
patient’s care. HCM is a heterogeneous disease. Symptoms, age of onset, the 
pattern and amount of left ventricle hypertrophy, existence of obstruction, and the 
patient’s risk for sudden cardiac death vary not only among patients, but also 
across family members who share a disease mutation (Ho, 2012). Therefore, a 
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specific mutation cannot normally predict anything additional about disease 
progression or severity.  
 Genetic testing’s greatest current practical value lies in helping to guide 
the management of the family. Once a disease-causing family mutation has been 
identified in the proband all first-degree relatives of the patient can and should be 
tested for the mutation. First-degree relatives are any children, siblings, or 
parents of the proband. They each have a 50% chance of carrying the disease 
mutation due to HCM’s autosomal dominant inheritance pattern. If they carry the 
mutation they are at risk to develop HCM and should undergo serial clinical 
screening. Those who do not carry the mutation are not at risk to develop HCM.  
A mutation carrier who wishes to have children can consider pre-
implantation genetic diagnosis. Using in vitro fertilization, early stage embryos 
can be tested for the HCM causing mutation. Then only embryos that do not 
carry the mutation will be implanted in an attempt to start pregnancy (Ho, 2012). 
Pre-implantation diagnosis can be especially useful in families where the 
mutation is associated with severe disease phenotypes. When many HCM 
patients with well-managed disease lead relatively normal, full lives, the majority 
of family members do not pursue this invasive technique.  
Preclinical HCM patients 
 The increased use of clinical genetic testing has created a new group of 
patients termed preclinical. Preclinical patients are genotype positive, carrying a 
disease-causing mutation, but phenotypically negative, meaning they have no 
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evidence of LVH on cardiac imaging. All preclinical HCM patients are 
asymptomatic. They may, however, show signs of HCM such as ECG 
abnormalities, or alterations on their echocardiograms (McKenna, et al., 1997).  
 We have also identified other markers that are associated with preclinical 
HCM. When Doppler tissue imaging is performed as part of an echocardiogram, 
we have seen diastolic dysfunction in the preclinical cohort. Diastolic function 
measurements in combination with ejection fraction, another measurement from 
an echocardiograph, were found to be a good predictor of preclinical disease 
(Ho, et al., 2002). In another study, impaired cardiac energetics seemed linked to 
preclinical HCM. This study looked at the relationship between levels of ATP and 
cardiac phosphocreatine and found it similar in HCM mutation carriers with and 
without LVH (Crilley, et al., 2003). A third study found an association between 
preclinical HCM and increased collagen synthesis. High levels of a serum protein 
that marks collagen turn-over were found in both preclinical and overt HCM 
patient cohorts (Ho, et al, 2010).  
The discovery and characterization of cardiac changes that occur before 
hypertrophy are a big step forward in our understanding of HCM. This new group 
of patients is an exciting population to study. We have the ability to identify an at-
risk population before we are even able to clinically diagnose these patients. This 
ability is a rare phenomenon in medicine. The more short-term good news for 
future patients is that we are becoming increasingly better at identifying HCM 
early. In families where genetic testing fails to find a disease-causing mutation 
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there are still research-based ways to look for disease in at-risk patients. More 
importantly, our ability to study mutation carriers gives us the unique opportunity 
to study early disease. Finding and studying changes in the preclinical patients, 
who have yet to develop disease, helps us learn more about HCM disease 
biology. We hope to ultimately develop a disease-modifying therapy based on 
these findings.  
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CURRENT STUDY 
We are investigating the rate of return of family members for clinical 
follow-up when their first-degree relative has a diagnosis of HCM. Since HCM is 
an autosomal dominant disease all first-degree family members of an HCM 
patient have a 50% chance of carrying the genetic information that makes them 
at-risk to develop disease. For this reason we consider disease management in 
terms of a family and not just the individual patient. In clinic, we advise each 
patient to have all of his or her children, siblings, and parents clinically evaluated 
for HCM. 
Maintaining longitudinal clinical care of this high-risk population is one of 
the most proactive parts of managing HCM. With adequate clinical care and 
follow-up most HCM patients live full lives with their day to day lifestyles only 
minimally limited by disease. The key to this type of disease management is 
identifying at-risk patients early. Then we can optimize the care an entire family 
receives. We are able to follow patients more closely when any symptoms 
change or present and when they are at an age when disease is most likely to 
develop. 
To determine the extent to which families are pursuing clinical follow-up 
for HCM, we are looking at a cohort of HCM patients seen at the Cardiovascular 
Genetics Clinic at Brigham and Women’s hospital who have clearly documented 
family information available. We want to determine what fraction of the patients’ 
family members return for follow-up of disease. There are many factors that may 
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influence who returns or does not return to clinic for evaluations. In this study we 
are looking for trends involving relationship to the proband, the presence or 
absence of genetic test results, and in cases where genetic testing has occurred, 
the classification of the identified mutations. 
We hope that learning more about what makes family members more 
likely to return will allow us to increase the percentage of family members who 
pursue follow-up for HCM in the future. Increasing the number of family members 
we test will both help us learn more about HCM and allow patients to take 
maximum advantage of the clinical treatment and management of HCM currently 
available. 
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METHODS 
We reviewed the records of all HCM patients who were evaluated at the 
Cardiovascular Genetic Center at Brigham and Women’s Hospital between 1998 
and 2012 and had pedigrees providing complete information about their first-
degree family members. These patients were seen in the HCM clinic, which is a 
subspecialty of the CVGC. We obtained information on the patients and their 
family members by querying the CVGC database of longitudinal patient records 
and supplementing with information from a review of their medical records.  
All new patients visiting the HCM clinic at the CVGC are provided full 
genetic counseling. They are also provided printed educational material 
describing HCM as an inherited disease, recommendations for clinical follow-up, 
and the genetic testing process. At each patient’s return visit they are reminded 
to seek screening for family members if they have not already done so. 
There were 361 patients who eligible for this study. The 361 patients have 
a total of 1,761 living first-degree relatives. We investigated the family history of 
each proband to determine which first-degree relatives, if any, pursued any type 
of follow-up, either clinical or genetic screening, through the clinic. We separated 
the first-degree relatives into categories based on their relationship to the 
proband: children, siblings, and parents. Each family has only one designated 
proband to facilitate classification of relationship and to ensure that no large 
families are counted multiple times in the study. The designated proband is either 
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the first family member to be evaluated in clinic or, in the case of genetic testing, 
the patient who underwent large-scale genetic screening first within the family. 
We divided the cohort based on genetic testing status, including a 
genotype positive group, genotype negative group, and not genetically tested 
group. Each proband in the genotype positive group has a disease-causing 
mutation identified. The genotype positive group can be further broken down by 
variant classification status as determined by the Laboratory for Molecular 
Medicine at the time the genetic testing was performed. The categories for 
variants that are considered mutation positive are pathogenic, likely pathogenic, 
and variant of unknown significance or VUS. The members of the genotype 
negative group underwent diagnostic genetic testing, but did not have a disease-
causing variant identified. In five probands, variants were classified as likely 
benign, and these patients were included in the genotype negative group. The 
third group contains all of the probands who did not pursue genetic testing. 
We performed hypothesis testing comparing proportions in different sized 
populations with significance set at 95%.  
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RESULTS 
A general profile of the 361 probands included in this study, grouped by 
genetic testing status, is presented in the table below.  
Table 1. Clinical Summary of HCM Probands**.  
 
 Genotype 
Positive 
Genotype 
Negative 
Not 
Genetically 
Tested 
All probands 
Number of 
Probands 144 78 139 361 
Age (years) 
average 
(range) 
 
44 
(16,80) 
 
51 
(19,83) 
 
49 
(15,85) 
 
48 
(15,85) 
Gender 
Number of 
males 
Number of 
females 
81 
 
63 
56 
 
22 
89 
 
50 
226 
 
135 
Number of 
probands 
with positive 
family history 
of HCM 
86 14 51 151 
Number of 
probands 
with positive 
family history 
of SCD 
56 18 40 114 
 
** Average age and gender breakdown of the probands are included. Additionally 
the presence or absence of both a family history of HCM and a family history of 
SCD were recorded in each proband. 
 
 
 In the study of 361 HCM patients seen in our clinic who had 
comprehensive family information recorded, the patients had a total of 1,761 first-
degree relatives. We grouped the family members by the genetic testing status of 
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the proband they are related to. Information about the first-degree relatives of the 
probands in each of the three groups is in the table below. 
Table 2. Summary of HCM Probands’ First-Degree Relatives**.  
 
 Genotype 
Positive 
Genotype 
Negative 
Not 
Genetically 
Tested 
Total 
Number of 
Probands 
144 78 139 361 
Number of 
Children 
258 127 224 609 
Number of 
Siblings 
328 148 320 796 
Number of 
Parents 
151 67 138 356 
Total 
number of 
relatives 
737 342 682 1761 
 
**The first row of this table shows how many probands fall into each of the 
genetic testing status groups. The rest of the table divides the probands’ relatives 
by both relationship to proband and genetic testing status as further described. 
The genotype positive group contains all family members related to a HCM 
patient who has a pathogenic, likely pathogenic, or VUS identified. The genotype 
negative group contains all family members related to an HCM patient who 
underwent genetic testing, but had no variant identified. The not genetically 
testing group includes the family members of HCM patients who did not opt to 
have genetic testing. 
 
 
Out of all 1,761 family members, we looked first to see who came back for 
any type of HCM-related follow-up including clinical evaluation only, genetic 
testing only, and both clinical and genetic testing. Overall, 39% of the family 
members pursued any type of follow-up. Children of probands sought follow-up 
at a rate of 46% returning, which is a slightly higher rate than the 35% of both 
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siblings and parents returning to clinic. The rate of children returning is also 
higher than the total percentage of relatives returning. 
 
Table 3. Overall Relatives Seeking Follow-up for HCM**. 
 
Overall Relatives Seeking Follow-up for HCM 
 % Returning for Follow-up 
Children *46% 
Siblings 35% 
Parents 35% 
Total 39% 
 
** Values are listed as percentages to account for patients’ ability to have 
multiple children and sibling, but only two biological parents. 
*Statistically significantly different from both % of siblings and % of parents 
returning for follow-up at a 95% confidence interval. 
 
 After looking at the percentages of all patients’ family members returning 
for any type of HCM examination, we divided the relatives by the genetic testing 
status of the proband. First we looked at genotype negative and not genetically 
tested probands’ families. Afterwards, we examined the slightly more complex 
genotype positive probands’ relatives. For these relatives, there are some cases 
where genetic testing is implicated, and we can compare rates of genetic and 
clinical follow-up. 
 Genotype negative proband’s family members pursued follow-up for HCM 
at 31% overall. Fewer children received evaluations for HCM, only 27%. More 
siblings, about 32%, and parents, about 36%, returned to the clinic for HCM 
evaluations. See data for genotype negative family members in the table below. 
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Table 4. Relatives of Genotype Negative Probands Seeking Follow-up for 
HCM**.  
 
Relatives of Genotype Negative Probands 
Seeking Follow-up for HCM 
 % Returning for Follow-Up 
Children 27% 
Siblings 32% 
Parents 36% 
Total 31% 
 
** Percentages of family members seeking clinical HCM screening, who are 
related to a proband who underwent genetic testing, but did not have a disease-
causing mutation identified. All percentages are not significantly different at a 
95% confidence interval. 
 
 When probands did not opt for HCM genetic testing, 32% of their relatives 
overall returned for HCM follow-up. This value is not statistically different from the 
31% of relatives who had follow-up in the genotype negative group. Among those 
who did not have genetic testing, 36% of children were clinically evaluated for 
HCM. This is higher than the overall percent return in this group. 29% of both 
siblings and parents return to clinic. This is not significantly lower than overall 
relatives seeking evaluations for HCM. A summary of this group’s data follows. 
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Table 5. Relatives of Not Genetically Tested Probands Seeking Follow-up 
for HCM**.  
 
Relatives of Not Genetically Tested Probands 
Seeking Follow-up for HCM 
 % Returning for Follow-up 
Children 36% 
Siblings 29% 
Parents 29% 
Total 32% 
 
** Percentages are separated by the family members’ relationship to the patient. 
All percentages are not significantly different at a 95% confidence interval. 
  
Last, we have the follow-up data for the relatives of HCM patients who 
have had disease-causing mutations identified upon genetic testing. The majority 
of these relatives are advised to have both genetic and clinical follow-up for 
HCM. Our data, as summarized in Table 6 shows how many of each type of 
relative pursued genetic testing, clinical HCM testing, or any follow-up for HCM at 
all. 
Table 6. Relatives of Genotype Positive Probands Seeking Follow-up for 
HCM**. 
 
Relatives of Genotype Positive Probands Seeking Follow-up for HCM 
 % Returning for 
genetic testing 
% Returning for 
clinical evaluations 
% Returning for any 
type of follow-up 
Children 44% 43% *64% 
Siblings 13% 40% 41% 
Parents 18% 32% 39% 
Total 25% 38% 48% 
 
** Percentages are separated by the family members’ relationship to the patient. 
Siblings, parents, and total relatives return for clinical evaluation at a higher 
percentage than genetic testing at a 95% confidence interval. 
*Statistically significantly different from both % of siblings and % of parents 
returning for any type of follow-up at a 95% confidence interval. 
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Overall trends show that more relatives pursue clinical than genetic 
testing. Children, however, pursue clinical and genetic testing at approximately 
equal rates. Children of mutation positive probands are followed up for HCM at 
64%. This is the highest rate of any group we studied. Siblings and parents seek 
follow-up at only 41% and 39% respectively. The Venn diagram below shows 
that while the highest proportion of relatives did not pursue any type of HCM 
follow-up, the majority of people tested had both clinical evaluations and genetic 
testing done. There are only a small amount of family members who had genetic 
testing, but were never screened clinically.  
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Figure 3. Proportional Venn Diagram of Genotype Positive Probands’ 
Relatives Pursuing Testing for HCM. Figure 3 groups the relatives related to a 
genotype positive proband by what type of HCM testing they pursued. 380 
relatives did not seek any HCM-related testing. 21 relatives had genetic testing 
only. 130 family members had clinical evaluations only. The remaining 206 
relatives had both genetic testing and clinical evaluations. 
 
 In the genotype positive cohort we separated the group further by variant 
classification of the mutation identified in the proband. Figure 4 shows how each 
of the subdivisions of the genotype positive group compare to the genotype 
negative and not genetically tested groups. Relatives of a proband with a 
pathogenic or likely pathogenic variant seek HCM-related follow-up about 50% of 
the time. Relatives of a proband with a variant of unknown significance seek 
follow-up significantly less with about 38% returning (significant at 95% 
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confidence interval). Family of probands who had genetic testing, but did not 
have a disease-causing mutation identified, returned at the lowest rate of 31%. 
However, a similar amount, 32%, of relatives of not genetically tested probands 
returned for HCM-related follow-up. 
 
Figure 4. Proportion of relatives screened by probands’ genetic testing 
status. The y-axis denotes the percentage of probands’ relatives who sought any 
type of HCM-related follow-up. The x-axis groups the relatives by the genetic 
testing status of the proband who the relative is related to. The genotype positive 
group is separated into three variant classification categories: pathogenic, likely 
pathogenic, and variant of unknown significance. The graph allows a comparison 
between the different subgroups of the genotype positive cohort and both the 
genotype negative and not genetically tested groups. The last bar is the total 
return rate, which includes all of the family members in the first 5 groups. 
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DISCUSSION 
 Overall, only 39% of the first-degree relatives of HCM patients treated in 
the CVGC clinic pursue HCM-related follow-up. This is a disappointingly low 
percentage. We advise 100% of first-degree relatives of HCM patients to seek 
clinical evaluations as this group has a 50% risk of inheriting HCM. When 
relatives are being screened at a rate lower than 50% there are certainly family 
members who have or will develop HCM that are not receiving proactive clinical 
care and management. 
 The CVGC HCM clinic is a highly specialized clinic. The team at the 
CVGC provides family counseling at every patient visit. They believe the best 
way to treat HCM is not only treating the patient, but treating the entire family. 
Each member of the team is actively involved in spearheading the latest HCM 
research. If return for family members is low for patients seen in this ideal clinic, it 
must be even lower for patients seen in less specialized cardiology clinics.  
 There are many reasons why family members may not pursue HCM-
related follow-up. First, it is inconvenient to schedule and take time to visit a 
doctor’s office. Just as people do not always visit their primary care physician for 
a yearly physical, people may not come to the cardiologist for HCM evaluation.  
Second, family members may be afraid to learn about a medical illness. 
When a family member has witnessed the medical problems related to HCM in 
his relative, he may prefer not to discover whether or not he too has HCM. He 
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may also fear discrimination from family, friends, work, or insurance companies if 
he is diagnosed with HCM.  
Third, parents of an HCM patient may not want to be evaluated for HCM 
because they would feel guilty for passing the disease onto their child. In 
autosomal dominant disease only one parent needs to transmit the disease. 
Discovering which parent is responsible for carrying and passing on the disease 
may introduce problems in the family dynamic. 
One of the reasons preventing family members from seeking HCM-related 
follow-up is lack of understanding in the proband, the family member, or both 
people. This factor is important, because we have the most influence over it. 
Every HCM patient is advised to bring his first-degree relatives to clinic for 
screening, and we provide referrals and resources to help. We, however, have 
no way of knowing how much the patient understood about the familial nature of 
HCM and its pattern of inheritance. Even when we believe the patient 
understands our message, we do not have control over how or if the patient 
transmits the message to his relatives. We also do not know how, in turn, the 
relative interprets the information. Some of our results suggest that patients may 
not be interpreting genetic test results properly. If this is true, we will have to 
rethink how to explain this information in the clinical setting.  
Another overall trend in our data is that children of probands return for 
HCM-related follow-up in the highest relative numbers. This is not surprising, 
because in any cases where children are under 18, their parent, the proband, 
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ultimately manages their health care. More generally, we expect that healthcare 
decisions by adult children are influenced by parental input. This trend suggests 
that the transmittal of advice, regarding HCM follow-up, between proband and 
relative may be where we lose relatives to return. We can interpret the data to 
mean that probands understand the message heard in clinic, but they have more 
success convincing their children that it is important to seek follow-up than they 
do convincing their siblings or parents.  
Interestingly, when looking at groups of relatives separated by proband 
genetic testing status, both genotype positive and not genetically tested groups 
have the highest return for follow-up in children. In the genotype negative group 
children are the least likely to return for HCM-related follow-up. The low levels of 
child follow-up in the genotype negative group is concerning, especially when 
children have the highest levels of follow-up in all other groups. When a proband 
is genotype negative, we advise him and his family to seek the same clinical care 
that they would have if they had not pursued genetic testing at all.  
These data suggest that parents are misinterpreting negative genetic test 
results. When we perform diagnostic genetic testing on a proband, we only 
sequence and analyze a subset of genes. There are many more genes that may 
contain HCM-causing mutations that are not included on this panel, because they 
have not yet been discovered. There are also certain genetic changes that may 
cause disease, but cannot be detected by this sequencing method. Current 
genetic testing only identifies a disease-causing mutation in 40-50% of HCM 
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patients (Ho, 2012). Negative genetic test results do not rule out a familial cause 
of HCM. If anything, family members of patients who are genotype negative 
should be coming to clinic more often than people in genotype positive families, 
because no family member can be ruled disease-free via genetic testing.  
How to Group Patients with a VUS Identified 
When grouping probands by their genotype status it is difficult to decide 
how to interpret the data on patients with variants of unknown significance. From 
the clinician’s point of view these patients are treated as genotype negative. 
When a variant of unknown significance is identified, advice for screening family 
members follows the same guidelines as if the patient either had negative 
genetic test results or never had genetic testing done. All first-degree family 
members are recommended for longitudinal clinical evaluations. Clinically, we 
treat the identification of a VUS as unhelpful information. We do not know 
anything more than we did before the genetic testing was ordered.  
However, when patients with a VUS receive the results of their genetic 
testing, we do inform them that they carry a variant. We also explain that we are 
uncertain of whether or not the variant explains their disease. We can never be 
sure of how the patient interprets the information. For the purposes of this study, 
we have included patients with a VUS identified as genotype positive. We did this 
because a truly genotype negative patient receives no information about variants 
identified, while a patient with a VUS does receive information about a variant in 
the results of their genetic testing. Looking at the group of patients with a VUS 
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separately from both the genotype positive group and the genotype negative 
group will help us see if the patients truly understand the genetic counseling that 
accompanies their genetic test results.  
38% of relatives with a VUS identified in their proband seek follow-up. This 
is roughly halfway between the approximate 50% of relatives in the genotype 
positive group and around 31-2% of the relatives in the genotype negative or not 
genetically tested groups. Families of patients with a VUS act differently from any 
of the other groups. While we advise probands with a VUS, negative genetic test 
results, and no genetic testing performed to seek family follow up the same way, 
patients with a VUS are more likely to seek family follow up. This suggests that 
genetic counseling’s emphasis on the ambiguity of a VUS and the importance of 
familial screening is better understood by these patients.  
Genotype negative and VUS identified probands are similarly engaged in 
their HCM medical care, because both groups sought genetic testing initially. It is 
more difficult to compare these groups to the not genetically tested group, 
because there are many reasons patients do not pursue genetic testing. Our data 
still suggests that patients understand the familial nature of disease and the need 
for family screening better when an ambiguous variant is found than when no 
variant is found during genetic testing. Understandably, patients do not recognize 
the similar ambiguity that exists in a negative genetic test result. Until we know all 
possible genetic causes of HCM, a genetic test can never rule out familial 
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disease. This confusion underscores the need for genetic counseling when any 
genetic testing is done. 
In the advent of whole genome sequencing becoming widely clinically 
available there will be genome reports with many VUS identified. Proper 
interpretation of these results is one of the largest problems with making whole 
genome sequencing available to the public. 
Reasons to Pursue Clinical Testing Only 
 There are many reasons why a patient may return for clinical evaluation 
but be uninterested in genetic testing. An important reason is the expense. 
Insurance companies will cover the cost of most clinic visits, but may require 
patients to pay out-of-pocket for genetic testing. It is not always possible to be 
absolutely sure that the insurance company will pay the cost of genetic testing at 
the time when the patient is in the clinic and available to give blood for the test. 
Extra time and energy is required to look into insurance policies and schedule an 
additional visit for genetic testing.  
 Additionally, there are emotional and psychological issues with genetic 
testing. Some people prefer not to know they carry a disease variant, because 
then they will worry about getting sick. Genetic test results can cause stress, 
feelings of guilt, and strain on family relationships.   
 Finally, while there are laws in place to protect patients from being 
discriminated against because of genetic test results, discrimination can still take 
place. Employers and health insurance companies have not been allowed to 
 35
treat patients differently because of their genetic information since the Genetic 
Information Nondiscrimination Act was passed in 2008. Life insurance 
companies, however, are not limited by this law. Patients interested in obtaining 
life insurance in the future may or may not face difficulties if they have genetic 
test results in their medical records.  
Limitations 
 There are a few major limitations of this study. First, this is an 
observational study. Groups were not systematically gathered or standardized. 
All of the data comes from observing and reviewing real world practice in the 
CVGC HCM clinic.  
Second, we were unable to capture information about familial follow-up 
that may be affected by geographic location. If any family members were 
evaluated remotely we are unlikely to have this data. The only means of 
capturing data on this group is if the proband reported the family information to 
the physician during his scheduled clinic visit and it was recorded in the patient’s 
family history.  
Third, age plays a large role in which relatives are recommended or likely 
to return for disease evaluation. Very young children or very elderly parents are 
less likely to come into the clinic for evaluation. Children are often not advised to 
come in for clinical evaluations until they are closer to puberty when LVH is more 
likely to develop (Maron, Seidman, & Seidman, 2004). 
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Fourth, this review occurred at a single point in time looking at past 
information. Patients who have had their first clinic visit more recently may not 
have had time to order and receive genetic test results. In turn, their family 
members may not yet have time to schedule and come in for either clinical or 
genetic testing. Additionally, families grow and change in size. Information to 
construct family histories is collected on or near each patient’s first visit. Changes 
and updates since the first visit are potentially unrecorded.  
Fifth, in this study we have only collected binary data. The relative either 
came to the clinic for follow-up at least one time or the relative did not come in for 
follow-up. We suggest that patients who are at-risk for HCM come in for 
longitudinal screening. If a patient has one normal clinical evaluation at a 
relatively young age, he is still at-risk for HCM and may develop it in the future. 
This review does not capture any data regarding whether family members have 
had multiple clinical encounters over an extended period of time as clinically 
advised.  
Sixth, in this study we only included living family members in our total 
counts of probands’ relatives. We did this because only living family members 
are able to return for follow-up. Including deceased family members would dilute 
the percentages of family members returning for HCM follow-up. However, there 
are families with severe disease phenotype and early onset disease where most 
affected family members were deceased at the time of this study. In these 
families we are not capturing a full record of which family members sought 
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clinical follow-up for HCM. The majority of probands in this study do not have this 
severe familial disease phenotype. Yet, there are many cases where one of the 
proband’s parents is deceased with a clear diagnosis of HCM. We are 
reasonably confident that the proband’s disease was inherited from this parent. 
The other living parent is then most likely not at-risk for HCM, and does not need 
a clinical evaluation for the disease. This may partially account for the low 
percentage of follow-up in parents of probands.  
Future Directions 
 One way to increase the numbers of HCM patients’ relatives returning for 
follow-up is to have a family clinic. A family clinic embodies our belief that the 
HCM patient is an entire family. The family clinic can increase convenience by 
scheduling a whole family to come into clinic together. The level of awareness of 
HCM within the family increases when a large clinic visit is being planned. The 
clinic will also help family members understand HCM and inheritance better. 
More people will listen to the physician at the same time. Individuals will feel 
more comfortable asking the physician questions, and there is built-in opportunity 
for open discussion.  
 Family based practices may also makes better use of time, as they can 
enable general (not personal or confidential) information to be provided to a 
group instead of repeated discussions at each individual’s appointment. 
Additionally, with more family members the physician is better able to collect an 
accurate and complete family history of disease. 
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 However, family clinics are only helpful when the patient has gone so far 
as to schedule a clinic appointment. The family clinic cannot help the many more 
people who have not made an initial appointment. In the future we need to find a 
way to target this unaided population for evaluations.  
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